|
|
|
|
Metagenomi Inc (NASDAQ: MGX) |
|
Price: $1.6900
$0.02 
1.198%
|
| Day's High:
| $1.7894
| Week Perf:
| 14.19 %
|
| Day's Low: |
$ 1.65 |
30 Day Perf: |
-3.98 % |
| Volume (M): |
672 |
52 Wk High: |
$ 4.91 |
| Volume (M$): |
$ 1,135 |
52 Wk Avg: |
$2.14 |
| Open: |
$1.66 |
52 Wk Low: |
$1.23 |
|
|
| Market Capitalization (Millions $) |
63 |
| Shares
Outstanding (Millions) |
37 |
| Employees |
51 |
| Revenues (TTM) (Millions $) |
45 |
| Net Income (TTM) (Millions $) |
-78 |
| Cash Flow (TTM) (Millions $) |
-73 |
| Capital Exp. (TTM) (Millions $) |
2 |
Metagenomi Inc
Company Address: 5959 Horton Street Emeryville 94608 CA
Company Phone Number: 871-4880 Stock Exchange / Ticker: NASDAQ MGX
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Management Changes
Published Wed, Jan 15 2025 1:55 PM UTC
Metagenomi Expands Le...
|
| Product Service News
Published Wed, Dec 11 2024 11:30 PM UTC
The advancement of genome editing tools has transformed the landscape of genetic engineering. At the recent Nature Conference RNA at the Bench and Bedside IV, Metagenomi introduced MGX-001, a cutting-edge gene editing solution utilizing the innovative MG29-1 nuclease. This article delves into the specificity and efficiency of this novel genome editing tool, highlighting i...
|
| Clinical Study
Published Tue, Dec 10 2024 2:17 AM UTC
Harnessing Genetic Innovation: Metagenomi s Promising Breakthrough in Hemophilia A Therapy Showcased at ASH 66th Annual Meeting Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow-up In an inspiring leap forward for genetic medicine and hemophilia management, Metagenomi ...
|
| Announcement
Published Thu, Nov 21 2024 6:20 PM UTC
In the dynamic landscape of biotechnology and drug discovery, the fortunes of companies can shift dramatically, leading to significant implications for investors. A recent wave of legal actions has emerged surrounding Metagenomi, Inc. (NASDAQ: MGX), a company that has captured attention in the sector but is now facing scrutiny due to investor losses.Levi & Korsinsky, LLP, a ...
|
| Clinical Study
Published Tue, Nov 5 2024 9:05 PM UTC
: Metagenomi, Inc. has announced that their latest preclinical data regarding hemophilia A, specifically the site-specific insertion of the Factor VIII gene, will be presented at the upcoming American Society of Hematology (ASH) 66th Annual Meeting. This development, highlighting sustainable Factor VIII expression in nonhuman primates, may advance therapeutic options for ind...
|
| Per Share |
Current |
| Earnings (TTM) |
-2.05 $ |
| Revenues (TTM) |
1.22 $
|
| Cash Flow (TTM) |
- |
| Cash |
6.1 $
|
| Book Value |
5.74 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.05 $
|
| Revenues (TTM) |
1.22 $ |
| Cash Flow (TTM) |
- |
| Cash |
6.1 $
|
| Book Value |
5.74 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Revenues Abstract |
|
 100 % |
of total Revenue |
| Ionis |
|
96.29 % |
of total Revenue |
| Affini-T |
|
3.71 % |
of total Revenue |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
8.73%